Chordia Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Hiroshi Miyake
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7yrs |
| CEO ownership | 1.3% |
| Management average tenure | no data |
| Board average tenure | 2yrs |
Recent management updates
No updates
Recent updates
CEO
Hiroshi Miyake (54 yo)
7yrs
Tenure
Mr. Hiroshi Miyake, Ph D., is Co-Founder of Chordia Therapeutics Inc. and serves as its President, Chief Executive Officer, and Representative Director since November 2017. He has experiences in drug disco...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7yrs | no data | 1.33% ¥ 224.1m | |
| Independent External Director | 2.1yrs | no data | no data | |
| Independent External Director | 2yrs | no data | no data | |
| Independent External Director | 2yrs | no data | no data | |
| Independent External Director | 2yrs | no data | no data |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Board: 190A's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.